Literature DB >> 9352537

Intratumoral microdistribution of [131I]MB-1 in patients with B-cell lymphoma following radioimmunotherapy.

R S Brown1, M S Kaminski, S J Fisher, A E Chang, R L Wahl.   

Abstract

Intratumoral microdistribution of radiolabeled anti-CD37 murine monoclonal antibody, [131I]MB-1, in lymph nodes from five patients with non-Hodgkin's B-cell lymphoma following radioimmunotherapy were evaluated by microautoradiography and image analysis of macroautoradiographs. Microdistribution of radioactivity was highly heterogeneous: silver grain counts varied from 28-70 to 8-10 per 400 X field, and the coefficients of variations calculated by image analysis ranged between 42.5 and 79.3%. Variable radiation doses delivered could have contributed to the limited durability of tumor regression.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9352537     DOI： 10.1016/s0969-8051(97)00099-1

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN： 0969-8051            Impact factor:   2.408


  9 in total

Review 1.  Clinical pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Ron J Keizer; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

2.  Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma.

Authors:  Heather Jacene; John Crandall; Yvette L Kasamon; Richard F Ambinder; Steven Piantadosi; Donna Serena; Wayne Kasecamp; Richard L Wahl
Journal:  Mol Imaging Biol       Date:  2017-06       Impact factor: 3.488

3.  Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.

Authors:  Sarwish Rafiq; Anthony Siadak; Jonathan P Butchar; Carolyn Cheney; Gerard Lozanski; Naduparambil K Jacob; Rosa Lapalombella; Jackie McGourty; Meghan Moledor; Richard Lowe; Ben Setter; Jeffrey Jones; Joseph M Flynn; Leslie Andritsos; Steven Devine; Xiaokui Mo; David Jarjoura; Susheela Tridandapani; Paul Algate; John C Byrd; Natarajan Muthusamy
Journal:  MAbs       Date:  2013-06-07       Impact factor: 5.857

4.  Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.

Authors:  Xiaobin Zhao; Rosa Lapalombella; Trupti Joshi; Carolyn Cheney; Aruna Gowda; Martha S Hayden-Ledbetter; Peter R Baum; Thomas S Lin; David Jarjoura; Amy Lehman; Donna Kussewitt; Robert J Lee; Michael A Caligiuri; Susheela Tridandapani; Natarajan Muthusamy; John C Byrd
Journal:  Blood       Date:  2007-04-17       Impact factor: 22.113

Review 5.  Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.

Authors:  Katherine L Gill; Krishna K Machavaram; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

6.  177Lu-DOTA-HH1, a novel anti-CD37 radio-immunoconjugate: a study of toxicity in nude mice.

Authors:  Ada H V Repetto-Llamazares; Roy H Larsen; Anna Maria Giusti; Elena Riccardi; Øyvind S Bruland; Pål Kristian Selbo; Jostein Dahle
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

7.  Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.

Authors:  Ada H V Repetto-Llamazares; Roy H Larsen; Sebastian Patzke; Karianne G Fleten; David Didierlaurent; Alexandre Pichard; Jean Pierre Pouget; Jostein Dahle
Journal:  PLoS One       Date:  2015-06-11       Impact factor: 3.240

8.  Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma.

Authors:  Ada H V Repetto-Llamazares; Roy H Larsen; Camilla Mollatt; Michael Lassmann; Jostein Dahle
Journal:  Curr Radiopharm       Date:  2013-03

9.  Quantitative intratumoural microdistribution and kinetics of (131)I-huA33 antibody in patients with colorectal carcinoma.

Authors:  Marika Ciprotti; Geoffrey Chong; Hui K Gan; Anthony Chan; Carmel Murone; Duncan MacGregor; Fook-Thean Lee; Terrance G Johns; Joan K Heath; Matthias Ernst; Antony W Burgess; Andrew M Scott
Journal:  EJNMMI Res       Date:  2014-05-30       Impact factor: 3.138
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.